3Ruggeri M, Tosetto A, Frezzato M, et al. The rate of progression to polyeythemia vera or essential thrombocythemia in patients with erythrocytosis or thromboeytosis [ J]. Ann Intern Med, 2003,139 (6) :470-475.
4Ishiguro A, Suzuki Y, Mito M, et al. Elevation of serum thrombo- poietin precedes thmmboeytosis in acute infections [J ]. Br J Haematol, 2002,116(3) :612-618.
5Gnatenko DV, Zhu W, Xu X, et al. Class prediction models of thrombocytosis using genetic biomarkers [ J ]. Blood, 2010, 115 (1) :7-14.
6Tefferi A. Polyeythemia vera and essential thmmbocythemia: 2013 update on diagnosis, risk-stratification, and management[ J]. Am J Hematol, 2013,88(6) :507-516.
7Hasserjian RP, Ott G, Elenitoba-Johnson KS, et al. Commentary on the WHO classification of tumors of lymphoid tissues (2008) : " Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma[J]. J Hematop, 2009,2(2) :89-95.
8Beer PA, Erber WN, Campbell PJ, et al. How I treat essential thrombocythemia [ J]. Blood, 2011,117 (5) : 1472-1482.
9Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecu- lar pathophysiology, essential clinical understanding, and treat- ment strategies[J]. J Clin Oncol, 2011,29(5) :573-582.
10Savage DG, Szydlo RM, Goldman JM. Clinical features at diagno- sis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period [ J ]. Br J Haematol, 1997,96( 1 ) :111-116.
